Fresenius SE & Co. KGaA: EPS $0.25 vs $0.23 expected
Key Facts
Q3 FY2026 results
| Metric | Actual | Estimate | Surprise | Year ago |
|---|---|---|---|---|
| EPS (USD) | 0.25 | 0.23 | +8.7% | 0.23 |
| Revenue (USD bn) | — | — | — | 6.29 |
Recent reports: actual vs estimate
| Reported | Period | EPS (USD) | Estimate | Surprise | Revenue (USD bn) | Estimate | Surprise |
|---|---|---|---|---|---|---|---|
| Nov 4, 2026 | Q3 FY2026 | 0.25 | 0.2300 | +8.7% | — | — | — |
| Aug 5, 2026 | Q2 FY2026 | 0.24 | 0.2500 | −4.0% | 6.85 | 6.65 | +3.0% |
| May 6, 2026 | Q1 FY2026 | 0.24 | 0.2535 | −5.3% | 6.75 | 6.79 | −0.5% |
| Feb 25, 2026 | Q4 FY2025 | 0.28 | 0.2690 | +4.1% | 6.93 | 6.89 | +0.7% |
| Nov 5, 2025 | Q3 FY2025 | 0.23 | 0.2080 | +10.6% | 6.29 | 6.38 | −1.5% |
| Aug 6, 2025 | Q2 FY2025 | 0.24 | 0.2182 | +10.0% | 6.57 | 6.10 | +7.7% |
| May 7, 2025 | Q1 FY2025 | 0.23 | 0.2093 | +9.9% | 6.19 | — | — |
| Feb 26, 2025 | Q4 FY2024 | 0.18 | 0.1810 | −0.6% | 5.83 | 5.58 | +4.4% |
Source: Figures from the EL7 database. Estimates are the analyst consensus carried by our data vendor (FMP), not official figures. Figures are in USD as carried for this US-traded line; the company reports in another currency.
Fresenius SE & Co. KGaA results: EPS $0.25 vs $0.23 expected. The results cover the company's Q3 FY2026. EPS came in above analysts' estimate by 8.7%. Revenue figures are not available yet. Figures are in USD as carried for this US-traded line; the company reports in EUR.
EPS was up 8.7% from $0.23 a year earlier. On its record, EPS topped analysts' estimates in 4 of 7 earlier comparable reports.
What the results mean
Fresenius combines medical care with medicines, technologies and healthcare facility projects. Its results therefore need to be understood through its business mix, since hospitals and outpatient care have different operating drivers from medical products and project services.
Kidney care serves people with renal diseases, while the medicines and technologies business focuses on lifesaving treatments. Care delivery includes inpatient services, outpatient services and telemedicine, making the mix across these activities important for understanding revenue sources and the nature of costs.
What to watch on the earnings call: Demand for care services and medical products, the contributions of kidney care, medicines and hospitals to performance, the cost structure and margins of each business, and the role of telemedicine and healthcare facility projects in the business mix.
For the full analysis of Fresenius SE & Co. KGaA stock — valuation, scores and financial statements — see the stock page linked with this story.